Sodium p-aminosalycilate (PASS) is an orphan drug used in patients affected with Multi-drug-resistant Tuberculosis (MDR-TB). In this article the preparation and characterization of a new alternative formulation of PASS is described. It consists of a powder for extemporaneous reconstitution to be orally administrated in solution, PASS/EXT. It is finally packaged in a tight closed, light resistant glass container as a unitary dose. In order to promote accessibility to MDR-TB treatment, the formulation is low cost and simple to manufacture, being compounded by only four ingredients. To improve patient compliance and treatment adherence, the unpleasant taste of PASS was masked and PASS/EXT is easy to drink. The PASS-EXT was characterized in relation to its content uniformity, time of blending, powder bulk properties (flowability), water sorption studies and stability. The proposed alternative formulation has remained stable in its final containers for 3 months, as demonstrated by analytical assays and flowabilty properties.